| Combination of | |
|---|---|
| Calcium acetate | Mineral supplement |
| Magnesium carbonate | Mineral supplement |
| Clinical data | |
| Trade names | OsvaRen, Renepho |
| AHFS/Drugs.com | UK Drug Information |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
  (what is this?) (verify) | |
Calcium acetate/magnesium carbonate is a fixed-dose combination drug that contains 110 mg calcium and 60 mg magnesium ions and is indicated as a phosphate binder for dialysis patients with hyperphosphataemia (abnormal high serum phosphorus levels).[1] It is registered by Fresenius Medical Care under the trade names Renepho (Belgium) and OsvaRen (a number of other European countries).
YouTube Encyclopedic
-
1/3Views:2 02711 99416 169
-
How to make Calcium Acetate
-
Calcium Acetate Nursing Considerations, Side Effects, Mechanism of Action Pharmacology for Nurses
-
How to Write the Formula for Calcium acetate
Transcription
Clinical use
Phosphorus is contained in food with high protein content as well as in processed food. It is absorbed by the small intestine.[2] Healthy kidneys remove excess phosphorus from the body. One of the consequences of renal failure is inadequate removal of phosphorus resulting in increased serum phosphorus levels. This may worsen the overproduction of parathyroid hormone (hyperparathyroidism), and may lead to renal osteodystrophy, calcification of blood vessels and is associated with cardiovascular mortality (the so-called chronic kidney disease-mineral and bone disorder, CKD-MBD).[3] In addition to dialysis therapy and dietary restrictions, a pharmaceutical therapy to lower serum phosphorus levels is recommended.[4]
Mechanism of action
Calcium acetate/magnesium carbonate is taken orally together with the meal.[1] Calcium acetate and magnesium carbonate compounds bind phosphorus derived from food thereby forming indigestible phosphate salts in the intestine that are subsequently excreted with the faeces. The aim of the therapy is to reach a normal serum phosphorus level, i.e. between 0.81 and 1.45 mmol/L (2.5–4.5 mg/dL).[3]
Side effects
Side effects from pharmaceutical therapy such as gastrointestinal disorders, e.g. nausea, constipation or diarrhoea may occur, as well as metabolism and nutritional disorders, e.g. hypercalcaemia or hypermagnesaemia.[1]
See also
References
- ^ a b c "OsvaRen 435 mg / 235 mg film-coated tablets" (PDF). Nottinghamshire, UK: Fresenius Medical Care. February 2011.
- ^ "Phosphorus". 23 April 2014.
- ^ a b Moe SM, Drüeke TB, Block GA, Cannata-Andía JB, Elder GJ, Fukagawa M, et al. (Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group) (August 2009). "KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)". Kidney International. Supplement. 76 (113 Suppl): S1–S2. doi:10.1038/ki.2009.188. PMID 19644521.
- ^ "What are medications for phosphorus control?". National Kidney Foundation. Retrieved 17 January 2010.
External links
- Phosphorus and Your CKD Diet – National Kidney Foundation
- Information on Hyperphosphataemia by Fresenius Medical Care – fmc-renalpharma.com
This page was last edited on 3 March 2024, at 23:50